Investigational drugs in PTSD.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology June 1, 2026 Ted Obi, Kerry J. Ressler
Post-traumatic stress disorder (PTSD) remains one of psychiatry's most challenging disorders, common, disabling, and biologically complex. Despite decades of research, only sertraline and paroxetine are FDA-approved, both with modest efficacy. Even first-line trauma-focused psychotherapies leave up to half of patients with persistent symptoms. However, advances in neurobiology are reframing...